Krystal Biotech, Inc. Common Stock

KRYSNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
313.66 USD
↗ 2.16 (0.69%)AT CLOSE (03:59 PM EDT)
312.94
↘ 0.72 (0.23%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
312.94
↘ 0.72 (0.23%)
🟢Market: OPEN

Shares of Krystal Biotech, Inc. Common Stock (KRYS) are trading at $312.94. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score and a bullish Golden Cross on the moving averages. Furthermore, KRYS is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Oct 26, 2026.

Open?$313.56
High?$317.76
Low?$309.63
Prev. Close?$311.50
Volume?223.6K
Avg. Volume?292.0K
VWAP?$312.89
Rel. Volume?0.77x
Bid / Ask
Bid?$260.31 × 40
Ask?$314.92 × 80
Spread?$54.61
Midpoint?$287.62
Valuation & Ratios
Market Cap?9.2B
Shares Out?29.6M
Float?22.8M
Float %?77.2%
P/E Ratio?38.18
P/B Ratio?6.78
EPS?$8.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
295
Market Cap
9.2B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.krystalbio.com
Listed
2017-09-20
Address
2100 WHARTON STREET
PITTSBURGH, PA 15203
Phone: (412) 586-5830
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
83
Short Sent.?
57
Piotroski F-Score?4/9Mixed
Altman Z-Score?40.69Safe
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?12.85%High
Short Interest?2.9M
Days to Cover?10.3
Free Float22.8M
Avg Daily Volume284.2K
Settlement Date2026-10-15
Financial Health
Current Ratio?8.32Strong
Quick Ratio?7.96Strong
Cash Ratio?3.36Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
39/100
P/E?
Peers
100
S&P
19
38.2PRICEY▾
P/B?
Peers
100
S&P
27
6.78FAIR▾
P/S?
Peers
100
S&P
3
20.93HIGH▾
P/FCF?
Peers
100
S&P
21
35.8PRICEY▾
EV/EBITDA?
Peers
100
S&P
3
43.2HIGH▾
EV/Sales?
Peers
100
S&P
3
19.96HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
61
17.8%STRONG▾
ROA?
Peers
50
S&P
89
16.1%STRONG▾
Cash Flow & Enterprise
FCF?$257.8M
Enterprise Value?$8.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist